Permissive versus restrictive temperature thresholds in critically ill children with fever and infection: a multicentre randomized clinical pilot trial.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
07 03 2019
Historique:
received: 03 01 2019
accepted: 10 02 2019
entrez: 9 3 2019
pubmed: 9 3 2019
medline: 1 10 2019
Statut: epublish

Résumé

Fever improves pathogen control at a significant metabolic cost. No randomized clinical trials (RCT) have compared fever treatment thresholds in critically ill children. We performed a pilot RCT to determine whether a definitive trial of a permissive approach to fever in comparison to current restrictive practice is feasible in critically ill children with suspected infection. An open, parallel-group pilot RCT with embedded mixed methods perspectives study in four UK paediatric intensive care units (PICUs) and associated retrieval services. Participants were emergency PICU admissions aged > 28 days to < 16 years receiving respiratory support and supplemental oxygen. Subjects were randomly assigned to permissive (antipyretic interventions only at ≥ 39.5 °C) or restrictive groups (antipyretic interventions at ≥ 37.5 °C) whilst on respiratory support. Parents were invited to complete a questionnaire or take part in an interview. Focus groups were conducted with staff at each unit. Outcomes were measures of feasibility: recruitment rate, protocol adherence and acceptability, between group separation of temperature and safety. One hundred thirty-eight children met eligibility criteria of whom 100 (72%) were randomized (11.1 patients per month per site) without prior consent (RWPC). Consent to continue in the trial was obtained in 87 cases (87%). The mean maximum temperature (95% confidence interval) over the first 48 h was 38.4 °C (38.2-38.6) in the restrictive group and 38.8 °C (38.6-39.1) in the permissive group, a mean difference of 0.5 °C (0.2-0.8). Protocol deviations were observed in 6.8% (99/1438) of 6-h time periods and largely related to patient comfort in the recovery phase. Length of stay, duration of organ support and mortality were similar between groups. No pre-specified serious adverse events occurred. Staff (n = 48) and parents (n = 60) were supportive of the trial, including RWPC. Suggestions were made to only include invasively ventilated children for the duration of intubation. Uncertainty around the optimal fever threshold for antipyretic intervention is relevant to many emergency PICU admissions. A more permissive approach was associated with a modest increase in mean maximum temperature. A definitive trial should focus on the most seriously ill cases in whom antipyretics are rarely used for their analgesic effects alone. ISRCTN16022198 . Registered on 14 August 2017.

Sections du résumé

BACKGROUND
Fever improves pathogen control at a significant metabolic cost. No randomized clinical trials (RCT) have compared fever treatment thresholds in critically ill children. We performed a pilot RCT to determine whether a definitive trial of a permissive approach to fever in comparison to current restrictive practice is feasible in critically ill children with suspected infection.
METHODS
An open, parallel-group pilot RCT with embedded mixed methods perspectives study in four UK paediatric intensive care units (PICUs) and associated retrieval services. Participants were emergency PICU admissions aged > 28 days to < 16 years receiving respiratory support and supplemental oxygen. Subjects were randomly assigned to permissive (antipyretic interventions only at ≥ 39.5 °C) or restrictive groups (antipyretic interventions at ≥ 37.5 °C) whilst on respiratory support. Parents were invited to complete a questionnaire or take part in an interview. Focus groups were conducted with staff at each unit. Outcomes were measures of feasibility: recruitment rate, protocol adherence and acceptability, between group separation of temperature and safety.
RESULTS
One hundred thirty-eight children met eligibility criteria of whom 100 (72%) were randomized (11.1 patients per month per site) without prior consent (RWPC). Consent to continue in the trial was obtained in 87 cases (87%). The mean maximum temperature (95% confidence interval) over the first 48 h was 38.4 °C (38.2-38.6) in the restrictive group and 38.8 °C (38.6-39.1) in the permissive group, a mean difference of 0.5 °C (0.2-0.8). Protocol deviations were observed in 6.8% (99/1438) of 6-h time periods and largely related to patient comfort in the recovery phase. Length of stay, duration of organ support and mortality were similar between groups. No pre-specified serious adverse events occurred. Staff (n = 48) and parents (n = 60) were supportive of the trial, including RWPC. Suggestions were made to only include invasively ventilated children for the duration of intubation.
CONCLUSION
Uncertainty around the optimal fever threshold for antipyretic intervention is relevant to many emergency PICU admissions. A more permissive approach was associated with a modest increase in mean maximum temperature. A definitive trial should focus on the most seriously ill cases in whom antipyretics are rarely used for their analgesic effects alone.
TRIAL REGISTRATION
ISRCTN16022198 . Registered on 14 August 2017.

Identifiants

pubmed: 30845977
doi: 10.1186/s13054-019-2354-4
pii: 10.1186/s13054-019-2354-4
pmc: PMC6407208
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

69

Subventions

Organisme : Department of Health
ID : HTA/15/44/01
Pays : United Kingdom
Organisme : Health Technology Assessment Programme
ID : 15/44/01
Pays : International

Références

Intensive Care Med. 2012 Jan 31;:
pubmed: 22290072
Lancet. 1997 Sep 6;350(9079):704-9
pubmed: 9291905
J Integr Plant Biol. 2011 Jan;53(1):7-13
pubmed: 21205176
Pediatr Crit Care Med. 2018 Mar;19(3):204-209
pubmed: 29227436
Surg Infect (Larchmt). 2005 Winter;6(4):369-75
pubmed: 16433601
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Intensive Care Med. 2018 Aug;44(8):1240-1248
pubmed: 29868973
Science. 1976 Jul 16;193(4249):237-9
pubmed: 935867
J Pediatr. 1989 Jun;114(6):1045-8
pubmed: 2656959
Arch Dis Child Educ Pract Ed. 2013 Dec;98(6):232-5
pubmed: 24046395
JAMA. 1975 Mar 24;231(12):1248-51
pubmed: 163931
N Engl J Med. 2015 Dec 3;373(23):2215-24
pubmed: 26436473
BMJ Open. 2015 Sep 18;5(9):e008522
pubmed: 26384724
PLoS One. 2012;7(1):e30077
pubmed: 22253887
N Engl J Med. 1997 Mar 27;336(13):912-8
pubmed: 9070471
Eur J Pediatr. 2017 Mar;176(3):423-427
pubmed: 28097438
Crit Care. 2018 Jun 4;22(1):144
pubmed: 29866165
BMJ. 2000 Jan 1;320(7226):50-2
pubmed: 10617534
Chin Med J (Engl). 2013;126(10):1809-13
pubmed: 23673091
Arch Dis Child Educ Pract Ed. 2016 Feb;101(1):49-53
pubmed: 26464416
Arch Dis Child. 2019 May;104(5):426-431
pubmed: 30087153
Crit Care Med. 2017 May;45(5):806-813
pubmed: 28221185
Nat Rev Immunol. 2015 Jun;15(6):335-49
pubmed: 25976513
Am J Respir Crit Care Med. 2012 May 15;185(10):1088-95
pubmed: 22366046

Auteurs

Mark J Peters (MJ)

Respiratory, Critical Care and Anaesthesia Unit, Paediatric Intensive Care, UCL Great Ormond Street Institute of Child Health, 30 Guildford Street, London, WC1N 1EH, UK. mark.peters@ucl.ac.uk.
Paediatric Intensive Care Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. mark.peters@ucl.ac.uk.

Kerry Woolfall (K)

Department of Psychological Sciences, North West Hub for Trials Methodology, University of Liverpool, Liverpool, UK.

Imran Khan (I)

Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.

Elisabeth Deja (E)

Department of Psychological Sciences, North West Hub for Trials Methodology, University of Liverpool, Liverpool, UK.

Paul R Mouncey (PR)

Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.

Jerome Wulff (J)

Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.

Alexina Mason (A)

Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.

Rachel S Agbeko (RS)

NHS Foundation Trust, Newcastle, UK.
Institute of Cellular Medicine, Newcastle University, Newcastle, UK.

Elizabeth S Draper (ES)

Department of Health Sciences, University of Leicester, Leicester, UK.

Blaise Fenn (B)

Patient and Parent representative, London, UK.

Doug W Gould (DW)

Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.

Abby Koelewyn (A)

Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.

Nigel Klein (N)

Infection, Inflammation and Rheumatology, UCL Great Ormond Street Institute of Child Health, London, UK.

Christine Mackerness (C)

NHS Foundation Trust, Newcastle, UK.

Sian Martin (S)

Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.

Lauran O'Neill (L)

Paediatric Intensive Care Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Samiran Ray (S)

Respiratory, Critical Care and Anaesthesia Unit, Paediatric Intensive Care, UCL Great Ormond Street Institute of Child Health, 30 Guildford Street, London, WC1N 1EH, UK.
Paediatric Intensive Care Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Padmanabhan Ramnarayan (P)

Respiratory, Critical Care and Anaesthesia Unit, Paediatric Intensive Care, UCL Great Ormond Street Institute of Child Health, 30 Guildford Street, London, WC1N 1EH, UK.
Children's Acute Transport Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Shane Tibby (S)

Evelina Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Kentigern Thorburn (K)

Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK.

Lyvonne Tume (L)

Faculty of Health and Applied Sciences, University of the West of England, Glenside Campus, Bristol, UK.

Jason Watkins (J)

Institute of Cellular Medicine, Newcastle University, Newcastle, UK.

Paul Wellman (P)

Evelina Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.

David A Harrison (DA)

Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.

Kathryn M Rowan (KM)

Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH